Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2012

01-05-2012 | Melanomas

A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities

Authors: Christy Y. Chai, MD, Jeremiah L. Deneve, DO, Georgia M. Beasley, MD, Suroosh S. Marzban, BA, Y. Ann Chen, PhD, Bhupendra Rawal, MS, Stephen R. Grobmyer, MD, Steven N. Hochwald, MD, Douglas S. Tyler, MD, Jonathan S. Zager, MD

Published in: Annals of Surgical Oncology | Issue 5/2012

Login to get access

Abstract

Background

Hyperthermic isolated limb perfusion (HILP) or isolated limb infusion (ILI) are well-accepted regional chemotherapy techniques for in-transit melanoma of extremity. The role and efficacy of repeat regional chemotherapy for recurrence and which salvage procedure is better remains debatable. We aimed to compare toxicities and clinical outcomes by procedure types and the sequence.

Methods

Data from 44 patients, who underwent repeat HILPs or ILIs from 3 institutions beginning 1997 to 2010, were retrospectively reviewed. Regional toxicity assessed by Wieberdink grade, systemic toxicity assessed by serum creatine phosphokinase level, length of hospital stay (LOS), response rates at 3 months after the procedure, and time to in-field progression (TTP) were analyzed.

Results

Of 44 patients, 46% were men and 54% women with a median age of 66 (range 29–85) years at diagnosis. The median follow-up was 21.4 (range 4–153) months. Of 70 ILIs and 28 HILPs, the following groups were identified: group A, ILI → ILI (n = 25); group B, ILI → HILP (n = 10); group C, HILP → ILI (n = 12); and group D, HILP → HILP (n = 3). The comparison of Wieberdink grade, serum creatine phosphokinase level, LOS, and response rate between procedures (HILP vs. ILI), between sequence (initial vs. repeat), and among their interactions showed no statistically significant differences. TTP after initial procedure did not differ between HILP and ILI (P = 0.08), and no survival difference was seen (P = 0.65) when TTP after repeat procedure was compared.

Conclusions

Most patients tolerated repeat regional chemotherapy without increased toxicity or LOS. No statistical difference in clinical outcomes was noted when comparing repeat procedures, even though repeat HILPs showed higher complete response compared to repeat ILIs.
Literature
1.
Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–32.PubMedCrossRef
2.
Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45–50.PubMed
3.
4.
Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429–37.PubMedCrossRef
5.
Noorda EM, Takkenberg B, Vrouenraets BC, et al. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol. 2004;11:491–9.PubMedCrossRef
6.
Feldman AL, Alexander HR Jr, Bartlett DL, et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol. 1999;6:562–7.PubMedCrossRef
7.
Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39–45.PubMed
8.
Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903–7.PubMedCrossRef
9.
Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg. 1985;150:32–5.PubMedCrossRef
10.
Hansson JA, Simert G, Vang J. The effect of regional perfusion treatment on recurrent melanoma of the extremities. Acta Chir Scand. 1977;143:33–9.PubMed
11.
Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63:2551–61.PubMedCrossRef
12.
Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer. 1993;29A:606–12.PubMedCrossRef
13.
Grunhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol. 2005;12:609–15.PubMedCrossRef
14.
Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer. 1997;80:2084–90.PubMedCrossRef
15.
Klop WM, Vrouenraets BC, van Geel BN, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg. 1996;182:467–72.PubMed
16.
Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115:1932–40.PubMedCrossRef
17.
Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 2000;92:179–81.PubMedCrossRef
18.
Eggermont AM, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer. 2011;47:2150–7.PubMedCrossRef
19.
Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.PubMedCrossRef
20.
Beasley GM, Tyler DS. Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanoma. Ann Surg Oncol. 2011;18:1814–8.PubMedCrossRef
21.
Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706–15.PubMedCrossRef
22.
Lindner P, Thompson JF, De Wilt JH, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30:433–9.PubMedCrossRef
23.
Klaase JM, Kroon BB, van Geel AN, et al. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer. 1993;71:2990–4.PubMedCrossRef
24.
Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003–13.PubMedCrossRef
25.
Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188:532–7.PubMedCrossRef
26.
Beasley GM, McMahon N, Sanders G, et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. 2009;115:4766–74.PubMedCrossRef
27.
Beasley GM, Riboh JC, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011;29:1210–5.PubMedCrossRef
Metadata
Title
A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities
Authors
Christy Y. Chai, MD
Jeremiah L. Deneve, DO
Georgia M. Beasley, MD
Suroosh S. Marzban, BA
Y. Ann Chen, PhD
Bhupendra Rawal, MS
Stephen R. Grobmyer, MD
Steven N. Hochwald, MD
Douglas S. Tyler, MD
Jonathan S. Zager, MD
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-2151-z

Other articles of this Issue 5/2012

Annals of Surgical Oncology 5/2012 Go to the issue

Colorectal Cancer

Impact of Race/Ethnicity on Prognosis in Patients Who Underwent Surgery for Colon Cancer: Analysis for White, African, and East Asian Americans

Breast Oncology

Six-Year Analysis of Treatment-Related Toxicities in Patients Treated with Accelerated Partial Breast Irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial

Endocrine Tumors

Is One Benign Fine Needle Aspiration Enough?

Breast Oncology

Scoring System Based on BI-RADS Lexicon to Predict Probability of Malignancy in Suspicious Microcalcifications

Hepatobiliary Tumors

Outcome of Microscopic Incomplete Resection (R1) of Colorectal Liver Metastases in the Era of Neoadjuvant Chemotherapy

Endocrine Tumors

Thyroid Cancer Detection with Dual-isotope Parathyroid Scintigraphy in Primary Hyperparathyroidism